ADMA Biologics, Inc.
ADMA
$20.11
$0.391.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 134.22M | 121.98M | 114.80M | 117.55M | 119.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 134.22M | 121.98M | 114.80M | 117.55M | 119.84M |
| Cost of Revenue | 58.60M | 54.76M | 53.71M | 54.22M | 60.18M |
| Gross Profit | 75.63M | 67.23M | 61.10M | 63.33M | 59.66M |
| SG&A Expenses | 23.05M | 23.37M | 25.37M | 24.59M | 19.58M |
| Depreciation & Amortization | 38.00K | 32.00K | 25.00K | 25.00K | 28.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.21M | 79.19M | 79.92M | 79.23M | 80.20M |
| Operating Income | 51.01M | 42.80M | 34.88M | 38.32M | 39.64M |
| Income Before Tax | 47.52M | 40.10M | 33.45M | 34.71M | 36.75M |
| Income Tax Expenses | 11.09M | 5.88M | 6.55M | -77.18M | 840.00K |
| Earnings from Continuing Operations | 36.43M | 34.22M | 26.90M | 111.90M | 35.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.43M | 34.22M | 26.90M | 111.90M | 35.91M |
| EBIT | 51.01M | 42.80M | 34.88M | 38.32M | 39.64M |
| EBITDA | 53.04M | 44.86M | 36.85M | 40.27M | 41.58M |
| EPS Basic | 0.15 | 0.14 | 0.11 | 0.47 | 0.15 |
| Normalized Basic EPS | 0.13 | 0.11 | 0.09 | 0.10 | 0.10 |
| EPS Diluted | 0.15 | 0.14 | 0.11 | 0.46 | 0.15 |
| Normalized Diluted EPS | 0.13 | 0.10 | 0.09 | 0.09 | 0.09 |
| Average Basic Shares Outstanding | 238.60M | 241.49M | 237.78M | 236.43M | 234.57M |
| Average Diluted Shares Outstanding | 244.66M | 248.61M | 244.68M | 245.90M | 244.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |